PharmaNet/i3 has been renamed to inVentiv Health, Inc. to reflect the closer alignment between the clinical segment and the company’s commercial and consulting services.
“As a top global CRO, renaming ourselves inVentiv Health Clinical demonstrates a company-wide commitment to our clinical clients, who will benefit from seamless, global access to a more robust range of services,” said Paul Meister, chief executive officer at inVentiv Health. “Clients can now access broad inVentiv talent with expertise across the product life cycle to deliver tailored solutions from product development through commercialization.”
Raymond Hill, who was appointed to lead inVentiv Health Clinical in December, said, “By connecting clinical research and staffing capabilities to consulting and commercial services, inVentiv can offer fully integrated solutions to pharmaceutical, biotechnology, generic drug and medical device companies in a way that cannot be matched by any other CRO in the industry. One example is our ability to assist clients in Late Stage trials by tapping both digital and adherence experts from other inVentiv companies. Through this approach we can help our clients simplify complex health economics and outcomes research trials.”